Astrazeneca PLC (AZN) Stake Held by PARK CIRCLE Co
PARK CIRCLE Co maintained its position in Astrazeneca PLC (NYSE:AZN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,400 shares of the company’s stock at the end of the second quarter. Astrazeneca PLC comprises approximately 2.2% of PARK CIRCLE Co’s investment portfolio, making the stock its 15th largest position. PARK CIRCLE Co’s holdings in Astrazeneca PLC were worth $3,900,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AZN. Meeder Asset Management Inc. bought a new position in Astrazeneca PLC during the second quarter valued at approximately $105,000. Salem Investment Counselors Inc. bought a new position in Astrazeneca PLC during the first quarter valued at approximately $107,000. Tower Research Capital LLC TRC raised its position in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock valued at $121,000 after buying an additional 3,782 shares during the period. Parallel Advisors LLC raised its position in Astrazeneca PLC by 27.1% in the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock valued at $138,000 after buying an additional 964 shares during the period. Finally, Westport Asset Management Inc. bought a new position in Astrazeneca PLC during the second quarter valued at approximately $170,000. 14.18% of the stock is currently owned by institutional investors.
Astrazeneca PLC (NYSE:AZN) opened at 29.44 on Tuesday. The firm has a market capitalization of $74.54 billion, a P/E ratio of 19.31 and a beta of 0.74. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The firm has a 50-day moving average price of $31.08 and a 200-day moving average price of $31.53.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.41 by $0.46. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s revenue for the quarter was down 9.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.83 EPS. Equities analysts forecast that Astrazeneca PLC will post $1.86 EPS for the current year.
The company also recently announced a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a $0.44 dividend. This represents a dividend yield of 2.98%. The ex-dividend date is Wednesday, August 9th. Astrazeneca PLC’s payout ratio is presently 44.92%.
Several research analysts have commented on AZN shares. Piper Jaffray Companies reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. Investec raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, July 28th. Pareto Securities raised Astrazeneca PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BidaskClub lowered Astrazeneca PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $33.39.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.